A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
This study is completed in France, in the United Kingdom, in Belgium, .... It focuses on Schizophrenia.
Key information made simple
What is this study testing?
This study is testing whether surveys or interviews may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may answer questionnaires, join interviews, or provide follow-up information, attend study visits with the research team. The registry lists locations in Belgium, France, Germany.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Chu Brugmann in Brussels, Centre Médico Psychologique De Courbevoie in Asnières-sur-Seine, and Centre Medico Psychologique in Cagnes-sur-Mer. Participation appears to center on questionnaires, assessments, or follow-up information rather than a study treatment. The main fit is usually matching the main diagnosis and being able to understand the study and consent, while common reasons not to take part include other treatments that could interfere with the study. The official record does not list a trial phase, which usually means the study is focused on observation rather than testing a staged treatment.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Janssen-Cilag International NV
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- Over 18 Years
- Official registry ID
- NCT03809325
- Official title
- A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
- Official source
- Official registry link
Want help reviewing this study?
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Belgium.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with schizophrenia; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Cilag International NV, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me
